Technology Commercialization Partners Competitors

5AM was founded in 2002 and pursues investments in advanced life science innovations, and seeks to be diversified across the biopharmaceutical therapeutics, and platform technologies. Within each sector, 5AM invests across multiple therapeutic areas and modalities and evaluates opportunities based on innovative platform technologies, corporate spin-offs and products with shorter development cycles. Content 5AM shares on this platform is not, and may not be relied on, in any manner, as legal, tax, investment, accounting or other advice or as an offer to sell or a solicitation of an offer to buy an interest in any private fund, special purpose or other investment vehicle sponsored by 5AM Ventures. Content 5AM shares on this platform is not an investment recommendation. For a full list of all 5AM portfolio companies, please visit: https://5amventures.com/portfolio/

Telegraph Hill Partners is a venture capital and growth equity firm dedicated to helping life science, medical device and healthcare companies achieve their growth objectives. When you work with us, you get an experienced team that knows how to drive growth and profitability while maintaining the vision and integrity of the organization.

Aisling Capital believes the next decade will be marked by a revolution in healthcare driven by new therapeutics generated by biotechnology. The completion of the human genome has given scientists new insights into the causes of human disease. These insights, combined with the past 20 years of developments in the biotechnology industry, are leading to rapid expansion of novel approaches toward the diagnosis, prevention, and treatment of life-threatening illnesses. These advances have led to an ever-increasing demand for capital to complete the development and commercialization of new therapeutics. Our goal is to support the leading global healthcare companies that are building on these technical and medical breakthroughs to commercialize new healthcare products.